ABCB1 Allele Polymorphism Is Associated with Virological Efficacy in Naïve HIV-Infected Patients on HAART Containing Nonboosted PIs But Not Boosted PIs

REFERENCES

• Sharom FJ, Yu X, Doige CA. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem. 1993;268:24197–24202.
   PubMed Web of Science ®Google Scholar
• Sankatsing SU, Cornelissen M, Kloosterboer N, Crommen-tuyn KM, Bosch TM, Mul FP, et al. Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. AIDS Res Hum Retro viruses. 2007;23:19–27.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kim CH, Tsuruo T, Gollapudi S. Preferential ex-pression and activity of multidrug resistance gene 1 prod-uct (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J Clin ImmunoL 1992;12:451–458.
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brock-moiler J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Nat/ Acad Sci USA. 2000;97:3473–3478.
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull. 2002;25:1391–1400.
   PubMed Web of Science ®Google Scholar
• Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz Ul, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189–199.
   PubMed Web of Science ®Google Scholar
• Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug re-sistance transporter 1: a pharmacogenetics study. Lancet. 2002359: 30–36.
   Google Scholar
• Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid viro-logic response in HIV-1 infected children. AIDS. 2005;19: 371–380.
   PubMed Web of Science ®Google Scholar
• Zhu D, Taguchi-Nakamura H, Goto M, Odawara T, Naka-mura T, Yamada H, et al. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antivir Ther 2004; 9:929–935.
   PubMed Web of Science ®Google Scholar
• Owen A, Chandler B, Back DJ. The implications of P-glycoprotein in HIV: friend or foe? Fund Clin PharmacoL 2005;19: 283–296.
   PubMed Web of Science ®Google Scholar
• Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS. 2003;17:1696–1698.
   PubMed Web of Science ®Google Scholar
• Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Influence of polymor-phisms within the CX3CR1 and MDR-1 genes on initial an-tiretroviral therapy response. AIDS. 2003;17:201–208.
   PubMed Web of Science ®Google Scholar
• Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, Weissbrich B. No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the vi-rological and immunological response in treatment na-ive HIV-positive patients. Ann Clin Microbiol Antimicrob. 2005;4:3.
   PubMedGoogle Scholar
• Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, et al. Pharmacogenetics of long-term re-sponses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis. 2005;192:1931–1942.
   PubMed Web of Science ®Google Scholar
• Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentre F, et al. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS. 2005;19:2127–2131.
   PubMed Web of Science ®Google Scholar
• Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and thera-peutic drug response: a critical review and recommen-dations for future research. Pharmacogenomics J. 2007; 7:154–179.
   PubMed Web of Science ®Google Scholar
• Bocket L, Cheret A, Deuffic-Burban S, Choisy P, Gerard Y, de la Tribonniere X, et al. Impact of human immuno-deficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 2005;10:247–254.
   PubMed Web of Science ®Google Scholar
• Yazdanpanah Y, Chene G, Losina E, Goldie SJ, Merchadou LD, Alfandari S, et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol. 2001;30:864–871.
   PubMed Web of Science ®Google Scholar
• Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 200111: 217–221.
   Google Scholar
• Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001;358:383–384.
   PubMed Web of Science ®Google Scholar
• Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr 2003;34:295–298.
   PubMed Web of Science ®Google Scholar
• Soles C, Simon N, Drogoul MP, Quaranta S, Frixon-Marin V, Bourgarel-Rey V, et al. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indi-navir in HIV-infected patients. Br J Clin Pharmacol. 2007; 64:353–362.
   PubMed Web of Science ®Google Scholar
• la Porte CJ, Li Y, Beique L, Foster BC, Chauhan B, Garber GE, et al. The effect of ABCB1 polymorphism on the phar-macokinetics of saquinavir alone and in combination with ritonavir. Clin Pharmacol Ther 2007;82:389–395.
   PubMed Web of Science ®Google Scholar
• Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovu-dine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006;42:441–449.
   PubMed Web of Science ®Google Scholar
• Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, et al. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics. 2005;15:599–608.
   PubMed Web of Science ®Google Scholar
• Janneh O, Jones E, Chandler B, Owen A, Khoo SH. Inhibi-tion of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopi-navir in cultured CD4 T cells and primary human lympho-cytes. J Antimicrob Chemother 2007;60:987–993.
   PubMed Web of Science ®Google Scholar
• Lucia MB, Rutella S, Leone G, Vella S, Cauda R. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr 200127: 321–330.
   Google Scholar
• Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol. 2007;73:1573–1581.
   PubMed Web of Science ®Google Scholar
• Chaillou S, Durant J, Garraffo R, Georgenthum E, Roptin C, Dunais B, et al. Intracellular concentration of protease in-hibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin Trials. 2002;3:493–501.
   PubMedGoogle Scholar
• Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, Na-kano M. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. Biol Pharm Bull. 2000;23:1528–1531.
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A "silent" polymor-phism in the MDR1 gene changes substrate specificity. Science. 2007;315:525–528.
   PubMed Web of Science ®Google Scholar
• Parmley JL, Hurst LD. How do synonymous mutations af-fect fitness? Bioessays. 2007;29:515–519.
   Google Scholar
• Komar AA. Silent SNPs: impact on gene function and phe-notype. Pharmacogenomics. 2007;8:1075–1080.
   PubMed Web of Science ®Google Scholar
• Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137–166.
   PubMed Web of Science ®Google Scholar